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Abstract
Purpose: The study aims to assess the feasibility of Tomotherapy-based image-guided radiotherapy (IGRT) to reduce the
aspiration risk in patients with non-laryngeal and non-hypopharyngeal cancer. A retrospective review of 48 patients
undergoing radiation for non-laryngeal and non-hypopharyngeal head and neck cancers was conducted. All patients had a
modified barium swallow (MBS) prior to treatment, which was repeated one month following radiotherapy. Mean middle
and inferior pharyngeal dose was recorded and correlated with the MBS results to determine aspiration risk.
Results: Mean pharyngeal dose was 23.2 Gy for the whole group. Two patients (4.2%) developed trace aspiration following
radiotherapy which resolved with swallowing therapy. At a median follow-up of 19 months (1–48 months), all patients were
able to resume normal oral feeding without aspiration.
Conclusion and Clinical Relevance: IGRT may reduce the aspiration risk by decreasing the mean pharyngeal dose in the
presence of large cervical lymph nodes. Further prospective studies with IGRT should be performed in patients with non-
laryngeal and non-hypopharyngeal head and neck cancers to verify this hypothesis.
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Introduction
Dysphagia and aspiration are common following radiotherapy
for head and neck cancer [1]. Aspiration is potentially life-
threatening as the cough reflex may be absent or ineffective
following head and neck cancer radiotherapy. Head and neck
cancer survivors with chronic aspiration following treatment may
develop anxiety and depression because of social isolation, which
may severely impact on their quality of life. Recent studies suggest
a correlation between radiation dose to the pharyngeal constrictor
muscles and the risk of tube feeding dependence following head
and neck radiotherapy [2,3]. New radiotherapy techniques such as
intensity-modulated radiotherapy (IMRT) may decrease dyspha-
gia severity and the need for gastrostomy tubes because of
decreased radiation dose to critical structures for swallowing.
Some institutions advocate shielding the larynx separately with a
midline block in the split-field (SF) IMRT technique to reduce
radiation dose to the larynx and the middle and inferior
constrictor muscles [4]. Since aspiration risk increases with
pharyngeal dose, the prevalence of aspiration should be reduced
following head and neck cancer treatment in those that have a
decreased dose to this region. However, in the presence of cervical
lymph nodes, a mid-line laryngeal block can under-dose the
cervical lymph nodes in close proximity to the larynx, leading to
regional recurrences [5]. Whole-field (WF) IMRT is often
advocated in the presence of cervical lymph nodes to ensure
adequate target coverage [6]. However, studies have demonstrated
WF-IMRT to deliver higher laryngeal and pharyngeal radiation
dose, leading to unnecessary complications such as laryngeal
edema and aspiration. In a previous dosimetric study comparing
WF-IMRT to Tomotherapy-based image-guided radiotherapy
(IGRT), we had demonstrated that IGRT may significantly reduce
the larynx, middle and inferior pharyngeal doses in non-laryngeal
and non-hypopharyngeal cancer without compromising target
coverage [7]. The dosimetric advantage of IGRT to spare
laryngeal edema correlated with a significant reduction in the
rate of severe laryngeal edema and improvement in the quality of
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the voice in patients treated with IGRT [8]. The current
retrospective study was performed to determine if low radiation
doses to these swallowing structures could decrease the aspiration
rate in this subset of head and neck cancer patients as well.
Materials and Methods
The medical records of 48 patients undergoing helical
Tomotherapy-based IGRT for head and neck cancer in non-
laryngeal and non-hypopharyngeal sites at the University of
Arizona Department of Radiation Oncology were retrospectively
reviewed following institutional review board (IRB) approval. The
University of Arizona IRB waived the patient consent requirement
because of the retrospective nature of this study, which was limited
to patient chart reviews. Laryngeal and hypopharyngeal cancers
were excluded from the study because they are associated with a
high rate of aspiration at diagnosis [9]. Prior to treatment, each
patient was simulated in a supine position with a head and neck
Aquaplast mask for treatment immobilization. A computed
tomography (CT) scan with and without intravenous (IV) contrast
for treatment planning was performed in the treatment position.
The head and neck areas from the vertex to the mid thorax were
outlined with a slice thickness of 3 mm. CT scan with IV contrast
was employed to enhance target volume delineation. Radiother-
apy planning was performed on the CT scan without contrast to
avoid possible interference of contrast density on radiotherapy
isodose distributions. Diagnostic positron emitting tomography
(PET)-CT scan imaging was also incorporated with the CT
planning when available. A 0.5 cm bolus was placed on any area
of the skin involved by the tumor and on any palpable cervical
lymph nodes. Normal organs at risk for complications were
outlined for treatment planning, including the spinal cord, brain
stem, cochlea, mandible, parotid glands, larynx, pharyngeal
muscles, eyes, and oral cavity. The tumor and grossly enlarged
lymph nodes on CT scan (CTV1) with a margin (PTV1) were
treated to 70 Gy in 35 fractions (2 Gy/fraction). The margins
were 0.5–1 cm circumferentially around CTV1 depending on the
anatomic location. The areas at high risk (PTV2) were defined as
at least 1 cm around the gross tumor and pathologic cervical
lymph nodes. The areas at low risk (PTV3) were defined as the
subclinical regional lymph nodes with 0.5 cm margins circumfer-
entially. PTV2 and PTV 3 were treated to 63 Gy and 56 Gy in 35
fractions respectively. Patients undergoing postoperative radiation
were treated to 66 Gy, 59.4 Gy, and 54 Gy in 33 fractions to
PTV1, PTV2, and PTV3, respectively. Minimal target coverage
was 95% for all targets with at least 99% of the prescribed dose
delivered to 100% of PTV1. The lymph nodes in the ipsilateral
neck, including the retropharyngeal lymph nodes, were treated to
the base of skull if there was any cervical lymph node enlargement
or PET – positive lymph nodes. Contralateral uninvolved lymph
nodes were treated prophylactically with the C1 vertebral body as
the superior border of the radiation field.
In the case of bilateral cervical lymph node involvement, both
necks were treated to the base of skull to avoid any marginal
misses. Mean dose to the parotid was kept below 2600 cGy if there
was no ipsilateral cervical lymph node enlargement. Dose
constraints for other normal organs at risk (OAR) were: spinal
cord (45 Gy), brain stem (50 Gy), optic chiasm (45 Gy), mandible
(70 Gy to less than 30% of the mandible). Doses to larynx and
pharyngeal muscles for non-laryngeal and non-hypopharyngeal
cancers were kept between 20–40 Gy if feasible, as it is our strict
policy that all PTV targets should be covered by at least the 95%
target dose. The larynx and pharyngeal muscles were contoured
from the hyoid bone (superior border) to the cricoid cartilage
(inferior border) following consultation with a radiologist. The
pharyngeal muscles outlined included the middle and inferior
pharyngeal constrictors muscles according to the guidelines
developed by Eisbruch et al [10].
The larynx and pharyngeal muscles would have been effectively
shielded from radiation with a laryngeal block in the conventional
supraclavicular field of the SF -IMRT technique [4].
It is our recommendation that all head and neck cancer patients
in our institution have a modified barium swallow (MBS)
immediately prior to radiotherapy to exclude silent aspiration.
The MBS was performed in the Department of Speech Pathology
by speech pathologists who were blinded to the patient’s cancer
stage. However, they were instructed that these patients were at
risk of aspiration. Patients with demonstrated aspiration on MBS
who were scheduled to undergo concurrent chemoradiation had
percutaneous gastrostomy (PEG) tube placement in anticipation of
severe weight loss from mucositis. Repeat MBS was performed
four to six weeks after treatment completion to assess aspiration
risk. Although some patients continued to experience mucositis at
four weeks following chemoradiation, excessive fibrosis may
decrease the effectiveness of swallowing therapy if MBS was
delayed [11]. Swallowing therapy and PEG tube feedings were
recommended for patients who developed aspiration after
radiotherapy. Patients with severe weight loss during treatment
also continued with PEG tube feedings. All patients had PET-CT
scans four and ten months after completion of treatment in
addition to regularly scheduled follow-up consisting of physical
exam and nasopharyngoscopy if indicated. The PEG tube was
removed if there was no evidence of aspiration on post-treatment
MBS, no evidence of disease on PET-CT scan after treatment,
and if the patient had recovered from any treatment-related
weight loss.
Patients with loco-regional recurrence underwent surgical
salvage, and the PEG tube was not removed in anticipation of
severe dysphagia post -surgery. All patients were monitored by a
team of experienced dietitians to assess their nutritional needsfol-
lowing treatment. The presence or absence of dysphagia,
continued weight loss, and other parameters such as total protein,
albumin, and pre-albumin were taken into consideration before
the decision to remove the PEG tube even in the absence of
aspiration was made.
Results
Among 170 head and neck cancer patients treated at the
University of Arizona Department of Radiation Oncology from
2007 to 2012, we identified 48 patients with non-laryngeal and
non-hypopharyngeal cancers who had both MBS immediately
prior to and following radiotherapy. The patients selected did not
have aspiration observed on the MBS prior to radiotherapy,
although they may have been experiencing abnormal swallowing
because of the cancer and/or previous surgery. Median age at
diagnosis was 57 years (range: 25–83 years). Forty-four were males
and four were females. The disease site distribution was:
oropharynx (24), oral cavity (12), parotid (4), unknown (2),
nasopharynx (3), maxillary sinus (2) and neck recurrence (1).
The two patients that had an unknown primary also had
submental lymph node metastases, which were resected. In both
cases, the primary was presumed to be an occult oral cavity lesion
and the larynx was not included in the radiotherapy fields. The
three patients that had a parotid primary also had cervical lymph
node metastases requiring bilateral neck irradiation. One patient
had locally advanced maxillary sinus cancer which invaded into
the cheek and also required bilateral neck irradiation. Another
Aspiration Risk and Tomotherapy
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patient had locally advanced maxillary sinus cancer and gross
lymph nodes metastases in the left neck. Breakdown by stage
demonstrated one stage I, six stage II, 13 stage III, 16 stage IVA,
ten stage IVB, one stage IVC, and one patient with recurrence.
Definitive concurrent chemoradiation was delivered to twenty-
eight patients. Thirteen patients received postoperative chemor-
adiation, four patients had postoperative radiotherapy alone, and
three patients had definitive radiotherapy alone.
Indications for postoperative chemoradiation were positive or
close margins after surgery or extracapsular lymph node extension.
Table 1 summarizes the patient characteristics.
The mean pharyngeal dose was 23.2 Gy (15.4–54 Gy) for the
whole group. The most common abnormalities observed on pre-
treatment MBS were decreased transit in the oral phase (5
patients), pooling in the vallecula (9 patients) and decreased
laryngeal elevation in the pharyngeal phase of swallowing (3
patients). Following radiotherapy, two patients (4.6%) developed
trace aspiration which resolved with swallowing therapy. Mean
pharyngeal dose was 17.8 Gy and 19.3 Gy for the two patients
with aspiration. The most common abnormalities observed on
post-treatment MBS were decreased transit or residue in the oral
phase (9 patients), decreased laryngeal elevation (4 patients),
reduced base of tongue contraction (8 patients), reduced epiglottic
inversion (4 patients), and pooling in the vallecula (13 patients). No
patient developed aspiration pneumonia following treatment.
At a median follow-up of 19 months (1–48 months), all patients
were able to resume normal oral feedings without aspiration.
Among the 38 patients who had prophylactic PEG tube placement
for chemoradiation (three declined tube placement), three
remained dependent on PEG tube feedings because of severe
weight loss, two were able to resume oral feedings but their PEG
tubes were kept because of the short follow-up (three months), and
one patient had severe dysgueusia and continued tube feedings
even though he had no dysphagia. The other 32 patients had their
PEG tubes removed four to 10 months after treatment. The delay
in removing the PEG tube was recommended by the dietitians to
ensure that the patients achieved their ideal body weight because
of the severe weight loss and/or chronic dysgueusia which
prevented the patient from having adequate nutrition. The three
patients who declined prophylactic PEG tube placement did not
have to undergo tubes feedings during or after treatment.
Discussion
To our knowledge, despite the relatively small number of
patients, this is the first study to report aspiration rate following a
pharyngeal musculature-sparing IGRT technique. No patient in
the study had aspiration at cancer diagnosis. Thus, the prevalence
of aspiration following radiotherapy was dependent on radiation
dose delivered to the swallowing structures. All patients had WF-
IGRT with the goal to limit the pharyngeal dose. We used the
WF-IGRT technique in the study to provide adequate dose
delivery to the low neck in the presence of cervical node metastases
and to reduce the risk of low neck recurrences associated with a
split field technique [5]. Mutliple studies have correlated the
radiation dose to the pharyngeal muscles to the presence of severe
dysphagia and/or aspiration. Fua et al [12] used the Common
Toxicity Criteria (CTC) scale to grade the severity of dysphagia
following WF-IMRT and SF-IMRT for nasopharyngeal cancers.
Patients who had CTC grade 3 required tube feedings. The WF-
IMRT was associated with a higher dose to the pharyngeal
muscles and severe dysphagia. Severe dysphagia and prolonged
tube feedings were reported more often in the WF-IMRT cohort
(mean pharyngeal dose 55.2 Gy) compared to the SF-IMRT
group (mean pharyngeal dose 27.2 Gy). The corresponding
median time to insertion of the feeding tube was 36 days and 38
days, respectively. The mean pharyngeal dose in our study was
23.2 Gy, similar to the SF-IMRT. In another study, Caglar et al
[3] investigated the aspiration risk following WF-IMRT of 96
patients with head and neck cancer of all anatomic sites, including
laryngeal and hypopharyngeal cancers (18%). MBS was per-
formed four to six weeks following treatment. There was no
pretreatment MBS. Thus, the prevalence of silent aspiration pre-
treatment could not be assessed in a population of patients which
might be at a high risk for aspiration because of the tumor subsites
included in the study. Aspiration was assessed according to the
Swallowing Performance Scale (minimal aspiration: grade 5,
severe aspiration: grade 6–7). Following treatment, 32% of the
patients developed grade 5–7 aspiration. It was unclear how many
Table 1. Patient characteristics.
Patient Number 48
Age Median 57
Range 25–83
Sex Male 44
Female 4
Squamous Histology 48
Tumor Sites Oropharynx 24
Oral cavity 12
Parotid 4
Unknown (submental metastases) 2
Nasopharynx 3
Paranasal sinus (maxillary) 2
Neck recurrence 1
Stages I 1
II 6
III 13
IVA 16
IVB 10
IVC 1
Recurrence 1
T stages Tx 2
T1 7
T2 13
T3 10
T4 15
Recurrence 1
Neck nodes N0 13
N1 15
N2 14
N3 6
Treatment Postoperative radiation 4
Radiotherapy alone 3
Postoperative chemoradiation 13
Chemoradiation 28
Follow-up (months) Median 19
Range 1–48
doi:10.1371/journal.pone.0056290.t001
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patients developed grade 5 aspiration. However, a high aspiration
rate was observed when the radiation dose to the inferior
pharyngeal muscles exceeded 52 Gy. High dose to the pharyngeal
muscles was associated with WF-IMRT and the inclusion of
patients with laryngeal and hypopharyngeal cancers. Thus, the
methodology performed by Caglar et al was very similar to our
study because the swallowing study was performed four to six
weeks after treatment. We do not distinguish between minimal and
severe aspiration because our aim was to correlate aspiration rate
and radiation dose to the pharyngeal muscles. However, we
demonstrated that IGRT by virtue of its rapid dose fall-off
compared to WF-IMRT may significantly reduce pharyngeal
muscle dose even in the presence of cervical lymph node
involvement and can significantly reduce the aspiration risk.
Figure 1 and 2 illustrated the ability of IGRT to spare the larynx
and pharynx from a high radiation dose, though the involved
adjacent cervical lymph nodes were treated to a curative dose of
radiation. Nguyen et al [13] recently reported excellent regional
control in head and neck cancer patients treated with WF-IGRT
in the presence of cervical lymph nodes. Only one out of 76
patients with either unilateral or bilateral cervical lymph nodes
developed regional recurrences. In another study correlating MBS
before and three months after WF-IMRT for oropharyngeal (31)
and nasopharyngeal (5) cancer, aspiration rate was 47% at three
months after treatment [14]. Mean dose to the pharyngeal
constrictors was 64 Gy. All patients who developed aspiration
received more than 60 Gy to the pharyngeal constrictors. Two
other studies also corroborated the correlation between high
radiation dose to the pharyngeal muscles and dysphagia three
months and 20 months after treatment [15,16]. Table 2 summa-
rizes these studies correlating dysphagia and aspiration with
pharyngeal muscle dose.
In studies reporting aspiration rates following either 3D-CRT,
SF-IMRT, or WF-IMRT in patients with non-laryngeal and non-
hypopharygeal cancers, the rates of aspiration ranged from 6.4–
54% [17–21]. If we excluded the study of Schwartz et al [20] who
used the SF-IMRT technique, aspiration rates ranged from 16–
54%. Table 3 summarizes the reported aspiration rates in the
literature for non-laryngeal and non-hypopharyngeal cancers.
Although controversy still exists about which swallowing
structures are critical and need to be spared to prevent long-term
dysphagia and aspiration, the studies that reported the least
Figure 1. Illustration of the potential of Tomotherapy to spare the pharyngeal muscles in a patient with locally advanced base of
tongue cancer and right neck nodal metastases treated with definitive concurrent chemoradiation. Despite the proximity of the gross
tumor and neck nodes treated to 70 Gy, mean pharyngeal muscle radiation dose was 22.5 Gy. A split field intensity-modulated radiotherapy
technique to shield the larynx and pharyngeal muscles would have underdosed the right neck nodes and gross tumor. The patient is in clinical
remission two years following treatment and has no difficulty with swallowing except for xerostomia as the parotid gland could not be spared.
doi:10.1371/journal.pone.0056290.g001
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amount of dysphagia and aspiration used techniques which
effectively decreased radiation dose to the larynx, and middle
and inferior pharyngeal constrictor muscles [12,20]. Thus, WF-
IGRT, by virtue of its laryngeal and pharyngeal muscle sparing
along with its decreased aspiration rate may be the technique of
choice for non-hypopharyngeal and non-laryngeal head and neck
cancer [8]. The additional advantage of WF-IGRT is the excellent
regional control in the presence of cervical lymph nodes because of
the delivery of high dose to these structures in the face of laryngeal
and pharyngeal muscle sparing [13].
Figure 2. Illustrating the potential of Tomotherapy to spare the pharyngeal muscles in a patient who had postoperative
chemoradiation for locally advanced base of tongue and bilateral neck metastases. Even though the right neck was dissected and
required radiation of the surgical bed and scars to 63 Gy, the pharyngeal muscles can still be spared from excessive radiation dose. The midline
laryngeal block with the split field intensity-modulated radiotherapy technique would have had underdosed the surgical scar and area of the surgical
bed located in close proximity to the larynx and the gross lymph nodes on the left side. The patient is in remission 13 month after treatment.
doi:10.1371/journal.pone.0056290.g002
Table 2. Mean pharyngeal dose (Gy) correlation with dysphagia severity or aspiration reported in the literature.
Study
Mean pharyngeal
dose (Gray) Critical Structures implicated Clinical endpoints
Time-frame following
treatment
Caglar et al [3] .52 Inferior constrictors larynx Aspiration (32%) 4–8 weeks
Fua et al [12] 55.2 Middle constrictors Inferior constrictors Prolonged tube feedings
(median time: 38 days)
36–38 days
Feng et al [14] .60 Superior constrictors Supraglottic larynz Aspiration (47%) 3 months
Levendag et al [15] 48–51 Superior constrictors Middle constrictors QOL questionnaires for dysphagia 3 months
Dirix et al [16] 50 Middle constrictors Inferior constrictors
Supraglottic larynx
QOL questionnaires for dysphagia 20 months
NA: not assessed; QOL: quality of life.
doi:10.1371/journal.pone.0056290.t002
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We should point out that swallowing is a complex mechanism
requiring a perfect coordination of multiple muscles within the
tongue, pharynx, and larynx. Functional alteration of any of these
structures may result in dysphagia and aspiration. Reduced tongue
strength, tongue base retraction, and delayed laryngeal vestibule
closure were commonly observed following chemoradiation for
head and neck cancer [22]. Thus, shielding of the larynx and
pharyngeal muscles may reduce the risk of aspiration but complete
elimination of aspiration following radiotherapy may not be
achieved because of high radiation dose to other swallowing
structures such as the base of tongue. As an illustration, the two
patients in our study who developed trace aspiration after
radiotherapy both had mean pharyngeal dose less than 20 Gy.
However, they did not require PEG tube feeding as their
aspiration resolved with swallowing therapy. At a median follow-
up of 19 months, all study patients were able to resume normal
oral feeding without evidence of aspiration. Long-term PEG tube
feeding was frequently linked to dysgueusia, which is commonly
observed after chemoradiation for head and neck cancer [23].
The limitations of the present study include the retrospective
nature of the study, the heterogeneity of the patient population
and treatment modalities, the small number of patients, and the
fact that we did not include patients with laryngeal or hypopha-
ryngeal cancer. However, in such patients, it would not be feasible
to spare the pharyngeal muscles from excessive radiation because
of the close proximity of these tumor subsites, which often
demonstrate invasion of the muscles in locally advanced stages.
Nevertheless, despite these caveats, sparing of the pharyngeal
musculature from excessive radiation may decrease aspiration
rate, and merits further investigation. Prospective studies with
large numbers of patients should be performed to assess the impact
of WF-IGRT on dysphagia and aspiration in patients with head
and neck cancer.
Conclusion
Tomotherapy-based IGRT may reduce the aspiration rate for
non-laryngeal and non-hypopharyngeal head and neck cancer
patients because of the decreased pharyngeal muscle dose.
Prospective studies should be performed to assess the potential
of IGRT to reduce treatment dysphagia and to possibly improve
patient quality of life.
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